Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = siRNA targeted to BACE-1

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 2756 KB  
Article
In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer’s Disease Therapy
by David Lee, Andrew M. Shen, Milin Shah, Olga B. Garbuzenko and Tamara Minko
Int. J. Mol. Sci. 2024, 25(19), 10357; https://doi.org/10.3390/ijms251910357 - 26 Sep 2024
Cited by 6 | Viewed by 3092
Abstract
Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine, and beta-site amyloid precursor protein-cleaving enzyme (BACE-1) siRNA, and their combination as a “triple-drug therapy” in treating Alzheimer’s disease (AD). Female [...] Read more.
Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine, and beta-site amyloid precursor protein-cleaving enzyme (BACE-1) siRNA, and their combination as a “triple-drug therapy” in treating Alzheimer’s disease (AD). Female APP/PS1 homozygous, transgenic mice were used as an AD model. The spatial short-term memory of the APP/PS1 mice was evaluated by a Y-maze behavioral test. IN-administered formulations demonstrated better short-term memory recovery than oral administration. Triple-drug therapy induced short-term memory recovery and lowered beta-amyloid (Aβ) 40 and 42 peptide levels and BACE-1 mRNA expression. Additionally, inflammatory cytokine mRNA expression was downregulated. This innovative approach opens new possibilities for Alzheimer’s disease treatment and nose-to-brain delivery. Full article
Show Figures

Figure 1

11 pages, 1781 KB  
Communication
Effect of Functional Inhibition of BACE1 on Sensitization to γ-Irradiation in Cancer Cells
by Keitaro Nakamoto, Sota Kikuhara, Hiroaki Fujimori, Barkha Saraswat, Zhongming Gao, Ankitha Vadi Velu, Zongxiang Zhang, Ying Tong, Shoji Imamichi, Tadashige Nozaki, Yasufumi Murakami and Mitsuko Masutani
Curr. Issues Mol. Biol. 2024, 46(1), 450-460; https://doi.org/10.3390/cimb46010028 - 2 Jan 2024
Cited by 2 | Viewed by 2658
Abstract
Developing strategies for the radiosensitization of cancer cells by the inhibition of genes, which harbor low toxicity to normal cells, will be useful for improving cancer radiotherapy. Here, we focused on a β-site of amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1; β-secretase, memapsin-2). [...] Read more.
Developing strategies for the radiosensitization of cancer cells by the inhibition of genes, which harbor low toxicity to normal cells, will be useful for improving cancer radiotherapy. Here, we focused on a β-site of amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1; β-secretase, memapsin-2). By functional inhibition of this peptidase by siRNA, it has also recently been shown that the DNA strand break marker, γH2AX foci, increased, suggesting its involvement in DNA damage response. To investigate this possibility, we knocked down BACE1 with siRNA in cancer cell lines, and sensitization to γ-irradiation was examined by a colony formation assay, γH2AX foci and level analysis, and flow cytometry. BACE1 knockdown resulted in the sensitization of HeLa, MDA-MB-231, U2OS, and SAOS cells to γ-irradiation in a diverse range. BACE1 knockdown showed a weak radiosensitization effect in osteosarcoma U2OS cells, which has a normal p53 function. HeLa and SAOS cells, which harbor p53 dysfunction, exhibited a greater level of radiosensitization. These results suggest that BACE1 may be a potential target for the radiosensitization in particular cancer cells. Full article
(This article belongs to the Special Issue Advanced Research of Ionizing Radiation in Cancers)
Show Figures

Figure 1

Back to TopTop